Evidence map›Paper›PMID 42298709›Full record

ReviewBiomarker research2026

The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease.

Demeke Geremew, Joanne T M Tan, Peter J Psaltis, Christina A Bursill

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Demeke GeremewVascular Research Centre, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
Joanne T M TanVascular Research Centre, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
Peter J PsaltisVascular Research Centre, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
Christina A BursillVascular Research Centre, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia. christina.bursill@adelaide.edu.au.

Funding

Medical Research Future Fund 2016053National Health and Medical Research Council 2029117National Heart Foundation of Australia FLF 106656
6 · The paper itself

Abstract

The asialoglycoprotein receptor 1 (ASGR1) has an established role as a hepatic receptor that clears desialylated glycoproteins from the bloodstream. Recently, its role in health and disease has expanded beyond this from cardiovascular to cancer and viral infection. Circulating ASGR1 is associated with elevated risk of coronary artery disease. Preclinical studies have reinforced this, showing ASGR1 inhibition reduces atherosclerotic cardiovascular disease. ASGR1 controls platelet lifespan and function, thereby regulating coagulation and thrombosis. It also facilitates entry of bacteria and viruses into host cells, causing immunomodulatory effects, and plays dual roles in cancer - promoting and suppressing tumorigenesis. This review provides an in-depth overview of the latest mechanistic insights underlying the roles of ASGR1 in health and disease and elaborates on the progress of ASGR1-targeted therapies.

Indexed as

Asialoglycoprotein receptorAtherosclerosisCancerImmunityInfectionLiver

Identifiers

PMID42298709
PMCPMC13520182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.